Stock Track | Harmony Biosciences Soars 5.28% Intraday on Q4 Revenue Beat and Strong 2026 Guidance

Stock Track02-24

Harmony Biosciences Holdings, Inc. (HRMY) saw its stock price soar 5.28% during intraday trading on Tuesday. The significant upward movement followed the company's release of its fourth-quarter and full-year 2025 financial results before the market opened.

The pharmaceutical company reported Q4 net product revenue of $243.78 million, surpassing the IBES consensus estimate of $240.4 million and representing a 21% year-over-year increase. The revenue growth was primarily driven by strong demand for its narcolepsy treatment, WAKIX. Furthermore, Harmony Biosciences reiterated its 2026 net revenue guidance for WAKIX, projecting it to reach between $1.0 billion and $1.04 billion, which would achieve blockbuster status for the drug.

While the company reported a decline in adjusted net income for the quarter, the market's positive reaction appears focused on the robust top-line performance and the confident outlook for its flagship product. The reiterated multi-billion dollar revenue target for the coming year signals management's expectation of sustained commercial strength and growth potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105253629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105253629","market":"sg","top_or_hot":-1,"title":"Stock Track | Harmony Biosciences Soars 5.28% Intraday on Q4 Revenue Beat and Strong 2026 Guidance","media":"Stock Track","content":"<p>Harmony Biosciences Holdings, Inc. (HRMY) saw its stock price soar 5.28% during intraday trading on Tuesday. The significant upward movement followed the company's release of its fourth-quarter and full-year 2025 financial results before the market opened.</p><p>The pharmaceutical company reported Q4 net product revenue of $243.78 million, surpassing the IBES consensus estimate of $240.4 million and representing a 21% year-over-year increase. The revenue growth was primarily driven by strong demand for its narcolepsy treatment, WAKIX. Furthermore, Harmony Biosciences reiterated its 2026 net revenue guidance for WAKIX, projecting it to reach between $1.0 billion and $1.04 billion, which would achieve blockbuster status for the drug.</p><p>While the company reported a decline in adjusted net income for the quarter, the market's positive reaction appears focused on the robust top-line performance and the confident outlook for its flagship product. The reiterated multi-billion dollar revenue target for the coming year signals management's expectation of sustained commercial strength and growth potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harmony Biosciences Soars 5.28% Intraday on Q4 Revenue Beat and Strong 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harmony Biosciences Soars 5.28% Intraday on Q4 Revenue Beat and Strong 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harmony Biosciences Holdings, Inc. (HRMY) saw its stock price soar 5.28% during intraday trading on Tuesday. The significant upward movement followed the company's release of its fourth-quarter and full-year 2025 financial results before the market opened.</p><p>The pharmaceutical company reported Q4 net product revenue of $243.78 million, surpassing the IBES consensus estimate of $240.4 million and representing a 21% year-over-year increase. The revenue growth was primarily driven by strong demand for its narcolepsy treatment, WAKIX. Furthermore, Harmony Biosciences reiterated its 2026 net revenue guidance for WAKIX, projecting it to reach between $1.0 billion and $1.04 billion, which would achieve blockbuster status for the drug.</p><p>While the company reported a decline in adjusted net income for the quarter, the market's positive reaction appears focused on the robust top-line performance and the confident outlook for its flagship product. The reiterated multi-billion dollar revenue target for the coming year signals management's expectation of sustained commercial strength and growth potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1105253629","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105253629","pubTimestamp":1771945063,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harmony Biosciences Holdings, Inc. (HRMY) saw its stock price soar 5.28% during intraday trading on Tuesday. The significant upward movement followed the company's release of its fourth-quarter and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc."},"translate_title":"股票赛道|Harmony Biosciences盘中飙升5.28%，因第四季度营收超出预期和强劲的2026年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":1},"content_text":"Harmony Biosciences Holdings, Inc. (HRMY) saw its stock price soar 5.28% during intraday trading on Tuesday. The significant upward movement followed the company's release of its fourth-quarter and full-year 2025 financial results before the market opened.The pharmaceutical company reported Q4 net product revenue of $243.78 million, surpassing the IBES consensus estimate of $240.4 million and representing a 21% year-over-year increase. The revenue growth was primarily driven by strong demand for its narcolepsy treatment, WAKIX. Furthermore, Harmony Biosciences reiterated its 2026 net revenue guidance for WAKIX, projecting it to reach between $1.0 billion and $1.04 billion, which would achieve blockbuster status for the drug.While the company reported a decline in adjusted net income for the quarter, the market's positive reaction appears focused on the robust top-line performance and the confident outlook for its flagship product. The reiterated multi-billion dollar revenue target for the coming year signals management's expectation of sustained commercial strength and growth potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105253629","isCrawlerRequest":true}